Risk factor
High price volatility
Profitability factor
Greatly overvalued vs peers
About
Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, A Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epilepsy encephalopathy; and XEN1101, A Kv7 potassium channel opener, which is in...
Company Valuation
Based on key historical and expected multiples, the stock is greatly overvalued relative to its peers.
Target Price
The average target price of XENE is 53 and suggests 30% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increase
Buy
Sell